A major global systematic review confirms that HPV vaccination programs are delivering substantial real-world reductions in multiple HPV-related outcomes, including cervical cancer.
Analyzing 63 studies from around the world, researchers found that HPV infections dropped by 58 to 100 percent, cervical precancers fell by 30 to 88 percent, genital warts declined by 60 to 90 percent, and invasive cervical cancer rates decreased by 70 to 88 percent.
The strongest protection was seen in settings where vaccine coverage reached at least 70 percent and vaccination occurred before sexual debut. School-based programs proved especially effective at driving high uptake.
Despite this progress, the review highlights persistent global gaps. Low- and middle-income countries continue to bear the highest burden of HPV-related cancers, with limited access to vaccination and screening. Expanding access and maintaining high coverage remain critical to global cancer prevention goals.
The findings reinforce HPV vaccination as a high-impact public health intervention with measurable population-level benefits.